REDWOOD CITY, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of sessions highlighting the company’s Lumivascular™ technology at the upcoming New Cardiovascular Horizons conference taking place next week in New Orleans from Tuesday, May 30, through Friday, June 2, 2017.
Avinger Lumivascular technology highlights include the following presentations by Patrick Muck, M.D., vascular surgeon at Good Samaritan Hospital in Cincinnati, Ohio:
Tuesday, May 30
- “Optical Coherence Tomography (OCT): Role in Modern Cath Lab,” Crescent City Ballroom, 12:50 – 1:00pm CT
Wednesday, May 31
- “First Look: 24-Month Outcomes from the Pivotal VISION Trial for OCT-Guided Directional Atherectomy,” Waldorf Astoria Ballroom, 11:20 – 11:28pm CT
Thursday, June 1
- “Minimally Invasive Endarterectomy: Using Optical Coherence Tomography (OCT) to Guide Precision Debulking,” Crescent City Ballroom, 8:24 – 8:32pm CT
Materials related to certain sessions listed above will be posted to Avinger’s website following their presentation at the conference.
About Avinger, Inc.
Avinger, Inc. is dedicated to radically changing the way peripheral artery disease (PAD) is treated. The company’s Lumivascular platform, the first-ever image-guided catheter-based systems to diagnose and treat patients with PAD, includes the Lightbox imaging console, the Ocelot family of catheters for chronic total occlusions, and the Pantheris® atherectomy device. Avinger is based in Redwood City, Calif. For more information, please visit www.avinger.com.
Public Relations Contact: